<HTML><HEAD><META http-equiv="Content-type" content="text/html;charset=UTF-8"></HEAD><BODY><DIV><P><BR>               <BR>               <BR>               17    PATIENT COUNSELING INFORMATION <BR>               <BR>                  <BR>                     See FDA-Approved Patient Labeling.<BR>                  <BR>               <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.1   Bleeding<BR>                     <BR>                        Patients should be informed of the possibility of serious bleeding and to report immediately any signs or symptoms suggestive of hemorrhage (unusual bleeding or easy bruising).<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.2   Myelosuppression<BR>                     <BR>                        Patients should be informed of the possibility of developing low blood cell counts; they should be instructed to report immediately should fever develop, particularly in association with any suggestion of infection.<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.3   Fluid Retention<BR>                     <BR>                        Patients should be informed of the possibility of developing fluid retention (swelling, weight gain, or shortness of breath)<BR>and to seek medical attention if those symptoms arise.<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.4   Pregnancy<BR>                     <BR>                        Patients should be informed that dasatinib may cause fetal harm when administered to a pregnant woman. Women should be advised of the potential hazard to the fetus and to avoid becoming pregnant. If SPRYCEL is used during pregnancy, or if the patient becomes pregnant while taking SPRYCEL, the patient should be apprised of the potential hazard to the fetus [see Warnings and Precautions (5.7)].<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.5   Gastrointestinal Complaints<BR>                     <BR>                        Patients should be informed that they may experience nausea, vomiting, or diarrhea with SPRYCEL. If these symptoms<BR>are significant, they should seek medical attention.<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.6   Pain<BR>                     <BR>                        Patients should be informed that they may experience headache or musculoskeletal pain with SPRYCEL. If these symptoms are significant, they should seek medical attention.<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.7   Fatigue<BR>                     <BR>                        Patients should be informed that they may experience fatigue with SPRYCEL. If this symptom is significant, they should seek medical attention.<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.8   Rash<BR>                     <BR>                        Patients should be informed that they may experience skin rash with SPRYCEL. If this symptom is significant, they should seek medical attention.<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.9   Lactose<BR>                     <BR>                        Patients should be informed that SPRYCEL contains 135 mg of lactose monohydrate in a 100-mg daily dose and 189 mg of lactose monohydrate in a 140-mg daily dose.<BR>                     <BR>                     <BR>                  <BR>               <BR>               <BR>                  <BR>                     <BR>                     <BR>                     17.10   Missed Dose<BR>                     <BR>                        If the patient misses a dose of SPRYCEL, the patient should take the next scheduled dose at its regular time. The patient should not take two doses at the same time.<BR>								<BR>                     <BR>                     <BR>                  <BR>               <BR>            <BR>         </P></DIV></HTML>